Critical

Persistent cyanosis in the newborn – diagnostic approach (hyperoxia test)

Cardiac vs respiratory cyanosis · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Persistent central cyanosis in a newborn requires rapid differentiation of cardiac from respiratory/other causes; the hyperoxia (nitrogen washout) test helps distinguish fixed intracardiac shunting from reversible pulmonary causes. This protocol covers the structured diagnostic work-up while stabilising the infant.

Red flags

  • Cyanosis unresponsive to 100% oxygen
  • Differential pre-/post-ductal saturations
  • Shock or collapse
  • Weak femoral pulses or a pathological murmur
  • Low SpO2 with a paradoxically normal PaO2 (methaemoglobinaemia)

Assessment

Differential diagnosis

  • Cyanotic congenital heart disease (e.g. transposition, tetralogy, TAPVC)
  • Persistent pulmonary hypertension of the newborn
  • Parenchymal lung disease (RDS/MAS/pneumonia)
  • Airway obstruction (choanal atresia, Pierre Robin)
  • Sepsis
  • Methaemoglobinaemia or polycythaemia

Investigations

  • Pre- and post-ductal SpO2 and four-limb assessment
  • Arterial blood gas in room air and in high-flow 100% oxygen (hyperoxia test)
  • Chest radiograph
  • ECG
  • Echocardiography (definitive for structural heart disease and PPHN)
  • Full blood count, blood glucose, blood culture and consider methaemoglobin level

Management

  • Confirm true central cyanosis (not peripheral/acrocyanosis) and check SpO2 pre- and post-ductally.
  • Stabilise airway, breathing and circulation; apply monitoring and obtain IV access.
  • Perform the hyperoxia test: measure a baseline pre-ductal (right radial) arterial PaO2, then deliver 100% oxygen for ~10 minutes and repeat the arterial PaO2.
  • Interpret: a PaO2 that rises to >150–200 mmHg suggests a respiratory cause; a PaO2 that stays low (<100–150 mmHg) despite 100% O2 suggests fixed cardiac shunting (cyanotic CHD) or severe PPHN.
  • Use SpO2 cautiously – arterial PaO2 is more discriminating because saturation can plateau near 100% and mask the difference.
  • Look for a pre-/post-ductal difference suggesting duct-dependent flow or PPHN.
  • If cyanotic duct-dependent CHD is suspected, start prostaglandin without waiting for definitive imaging.
  • Obtain urgent echocardiography to define the diagnosis.
  • Treat reversible causes in parallel (sepsis, lung disease, airway obstruction).
  • In suspected methaemoglobinaemia (low SpO2 with normal PaO2, chocolate-brown blood), consider methylthioninium chloride.
  • Avoid high FiO2 harm in preterm/PPHN once a cardiac cause is identified.
  • Refer to cardiology/tertiary centre as dictated by the diagnosis.

Drugs & doses

Prostaglandin E1 (alprostadil) 5–20 nanogram/kg/min IV to maintain ductal patency for suspected duct-dependent cyanotic CHD
100% oxygen via headbox/high-flow for the hyperoxia test
Inhaled nitric oxide 20 ppm for confirmed PPHN
Methylthioninium chloride (methylene blue) 1–2 mg/kg IV over 5 min for methaemoglobinaemia
0.9% sodium chloride 10 mL/kg IV for shock

Disposition

NICU with cardiology access and echocardiography; start prostaglandin for suspected duct-dependent lesions; transfer to a cardiac centre once a cardiac cause is confirmed.

Complications & pitfalls

  • Delayed diagnosis of duct-dependent CHD with collapse
  • Hyperoxic injury if high FiO2 continued inappropriately
  • Apnoea from prostaglandin
  • Progressive hypoxaemia and acidosis
  • Multi-organ injury

Exam pearls

  • A failed hyperoxia test (PaO2 remaining low) points to cardiac disease or severe PPHN.
  • Use arterial PaO2, not just SpO2, to interpret the hyperoxia test.
  • When in doubt with a sick cyanosed baby, start prostaglandin – it is reversible and potentially life-saving.
  • Normal PaO2 with low SpO2 and brown blood means methaemoglobinaemia.
  • Echocardiography is the definitive test – arrange it urgently.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.